Wendy Novak Diabetes Institute
The Wendy Novak Diabetes Institute, part of Norton Children’s and affiliated with the University of Louisville School of Medicine, is one of the major TrialNet Affiliates at the forefront of type 1 diabetes research. Led by Kupper Wintergerst MD, the TrialNet team at the Wendy Novak Diabetes Institute is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Our Team
Kupper Wintergerst, MD
DirectorKupper A. Wintergerst, M.D., earned his medical degree from the University of Louisville. He completed his residency in pediatrics at the University of Florida College of Medicine and a fellowship in pediatric endocrinology at Stanford University School of Medicine in California. Dr. Wintergerst has been instrumental in growing the scope of care for children and adolescents with endocrine conditions. He is executive director of Wendy Novak Diabetes Institute, which was formed to expand clinical care, education and research to serve children and adults living with diabetes. Under Dr. Wintergerst’s leadership, Norton Children’s is recognized as a top program nationally in pediatric diabetes and endocrinology by U.S. News & World Report. Dr. Wintergerst is involved in international research efforts focused on diabetes mellitus, with the goals of improving life for patients, preventing the disease and, ultimately, curing Type 1 diabetes. He has been a primary investigator with TrialNet for 13 years.
Shannon Hall, BSN, RN
Clinical Research CoordinatorGwen Pierce, MSN, RN, CCRC
Clinical Research CoordinatorResearch Studies
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More
TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Details
